Advances in Myositis Treatment

Myositis, medically known as inflammatory myopathy, represents a complex family of rare autoimmune disorders in which the body’s immune system turns against its own skeletal muscles. Over the past few decades, the understanding of this condition has transformed dramatically. What was once broadly labelled as polymyositis or dermatomyositis is now recognised as a spectrum of distinct subtypes, each with unique clinical behaviour, organ involvement, antibody profiles, and response to therapy.

For patients in India, where awareness of autoimmune diseases is still evolving, these advances are not merely academic. They directly influence how early a patient is diagnosed, how accurately the subtype is identified, and how effectively myositis treatment is planned.

From a Single Disease to a Spectrum

Myositis was first described in 1863. By 1975, physicians recognised two main forms: polymyositis and dermatomyositis. Today, classification has expanded to include:

Dermatomyositis (DM)
Anti-synthetase syndrome (ASS)
Immune-mediated necrotizing myopathy (IMNM)
Inclusion body myositis (IBM)

Interestingly, what was once called polymyositis is now considered rare, with many past cases reclassified into newer subgroups based on autoantibody testing and biopsy findings.

This shift has changed treatment philosophy. Myositis is no longer treated as one disease but as multiple related disorders requiring individualised strategies.

Understanding Triggers and Risk Factors

Modern research shows that myositis develops due to a combination of genetic susceptibility and environmental triggers.

Strongly supported triggers include:

Ultraviolet radiation, especially linked to dermatomyositis. Incidence increases closer to the equator, making sun protection relevant in India.
Smoking, closely associated with anti-synthetase syndrome and lung involvement.
Statins, which in rare cases trigger autoimmune necrotizing myopathy.
Underlying cancers, particularly in dermatomyositis and polymyositis, where 10 to 30 percent of patients may have associated malignancy.

Infections are frequently reported before symptom onset but remain inconsistently linked and unproven as direct causes.

This knowledge has led to preventive advice such as UV protection, smoking cessation, careful monitoring of statin-related symptoms, and mandatory cancer screening in new diagnoses.

Why Early Myositis Diagnosis Changes Outcomes

One of the most important discoveries in recent decades is that starting treatment within one month of symptom onset significantly improves muscle recovery and long-term function.

Delayed diagnosis often leads to irreversible muscle damage, disability, and complications involving lungs or swallowing muscles. Tools such as:

Myositis-specific autoantibody panels
Muscle MRI
EULAR/ACR 2017 classification criteria
Focused cancer screening protocols

have improved diagnostic precision and allowed physicians to tailor therapy from the outset.

Steroids: Still the Backbone, but Used More Wisely

Glucocorticoids revolutionised autoimmune treatment in the 1950s and remain the first-line therapy for most myositis subtypes.

Typical practice includes:

Prednisone around 1 mg per kg per day
Intravenous methylprednisolone pulses for severe cases such as dysphagia or respiratory weakness

Steroids act rapidly through both genomic and non-genomic pathways, suppressing multiple inflammatory cells at once. However, long-term use comes at a cost.

Up to 97 percent of patients experience steroid side effects, including:

Osteoporosis and fractures
Diabetes and hypertension
Mood changes and weight gain
Steroid-induced muscle atrophy
Increased infection risk

This has driven a major shift towards steroid-sparing strategies.

The Rise of Steroid-Sparing Immunosuppressants

To reduce steroid exposure while maintaining disease control, early combination therapy is now standard in many centres.

Common agents include:

[table]

These medications allow gradual tapering of steroids while preventing relapse.

Biologics and Targeted Therapies: A New Era

Recent years have seen the entry of biologic agents and targeted immune therapies in refractory myositis.

Rituximab has shown benefit in difficult cases, especially anti-synthetase syndrome with lung disease.
Abatacept improves quality of life and disease activity.
JAK inhibitors such as tofacitinib show promise in refractory skin disease and MDA5-associated lung disease.
IVIG has emerged as a powerful option, especially in dermatomyositis, with faster action than steroids as demonstrated in the ProDERM trial.

IVIG is increasingly used upfront in severe cases or when steroid toxicity is a concern.

Inclusion Body Myositis: The Therapeutic Challenge

IBM remains largely resistant to steroids and immunosuppressants. Management focuses on:

Physiotherapy
Fall prevention
Swallowing care
Assistive devices

Research continues, but current care is supportive rather than curative.

Cancer Screening as Part of Myositis Treatment

A major advancement is recognising cancer screening as an integral part of myositis management, especially in dermatomyositis.

High-risk features include:

Older age
Dysphagia
TIF1-gamma and NXP2 antibodies
Severe skin disease

CT scans of chest, abdomen, and pelvis along with age-appropriate tests such as mammography, colonoscopy, Pap smear, and ovarian screening are recommended within the first three years of diagnosis.

The Essential Role of Physiotherapy

Earlier, patients were advised rest. Now, evidence shows that structured exercise:

Improves muscle strength and endurance
Reduces inflammation
Restores mitochondrial function
Prevents disability

Physiotherapy begins alongside medical treatment, not after recovery.

Multidisciplinary Care: The Modern Model

Effective myositis care now involves:

Rheumatologists
Neurologists
Dermatologists
Pulmonologists
Physiotherapists
Occupational therapists
Psychologists

Tertiary centres and emerging Centres of Excellence for Autoimmunity in India are making such integrated care possible.

What These Advances Mean for Patients in India

For Indian patients, these developments translate into:

Earlier and more accurate myositis diagnosis
Personalised treatment based on antibody profile and organ involvement
Reduced steroid complications
Better survival and quality of life
Increased awareness of cancer association
Greater role of physiotherapy and self-care

Awareness remains the first barrier. Many patients still reach specialists late because early symptoms are dismissed.

Looking Ahead: The Future of Myositis Treatment

Research is now focusing on:

Interferon-targeted therapies
Better biologics for muscle disease
Identifying consistent environmental triggers
Expanding access to antibody testing and MRI diagnostics
Clinical trials for refractory myositis

As understanding deepens, treatment is moving from broad immunosuppression to precise immune modulation.

Myositis is no longer an obscure, poorly understood muscle disease. It is a clearly defined spectrum of autoimmune disorders with evolving, evidence-based management strategies. Advances in antibody testing, imaging, cancer screening, steroid-sparing therapies, biologics, IVIG, and physiotherapy have dramatically improved patient outcomes.

For those living with autoimmune diseases in India, these advances offer hope. With early myositis diagnosis, tailored myositis treatment, and multidisciplinary support, patients today can expect better function, fewer complications, and a significantly improved quality of life compared to decades past.

FAQs

Q1. Why do doctors start treatment with steroids if they have so many side effects?
Steroids act quickly and powerfully to control the intense muscle inflammation seen in inflammatory myopathy. They stabilise the disease while slower, safer immunosuppressive medicines begin to work. The goal is not long-term steroid use, but early control followed by gradual tapering with the help of steroid-sparing drugs.

Q2. How do doctors decide which immunosuppressant or biologic medicine is right for a patient?
Treatment choice depends on the myositis subtype, organ involvement such as lungs or skin, autoantibody profile, severity of muscle weakness, and the patient’s overall health. For example, mycophenolate is preferred in lung disease, while IVIG may be chosen in severe dermatomyositis. This personalised approach is a major advance in recent years.

Q3. Is physiotherapy really as important as medicines in myositis?
Yes. Research now shows that guided exercise improves muscle strength, reduces inflammation, and prevents long-term disability. Physiotherapy is started alongside medical treatment, not after recovery, and is considered a core part of management.

Q4. Why is cancer screening necessary after a myositis diagnosis?
Certain types of myositis, especially dermatomyositis, are strongly associated with hidden cancers. The immune system’s reaction to cancer cells may trigger muscle and skin inflammation. Early screening helps detect malignancy at a treatable stage and is now a routine part of care.

Q5. Are newer treatments like IVIG and biologics available in India?
Yes, many tertiary care hospitals and specialised centres in India now offer advanced therapies such as IVIG, rituximab, and other biologics for patients who do not respond to conventional treatment. Access may vary by location, but awareness and availability are steadily improving.